Retatrutide: indexed trial records

This page carries 12 of the 194 records the literature query returned for Retatrutide, selected by citation count and preferring records that name the compound in their title. It is a selection, not a complete index.

Every row below resolves to a real identifier and names the study model the indexer assigned. The record class is read from the publication type on the record itself. Nothing here states what a record found.

At a glance

Class

Incretin receptor agonists

Receptor targets as recorded

GIP receptor, GLP-1 receptor, Glucagon receptor

Records indexed here

12

Records returned by the query

194

Publication years covered

2025–2026

Query retrieved

2026-10-10

Shape of the indexed record set

Study model is the indexer’s own assignment, taken from the MeSH population headings and the publication type. It is not a judgement about how well a record was conducted.

Endpoint coverage

1 of the 12 records here carry no subject heading from any endpoint set used on this site, so they appear under no endpoint.

Derived record-set tier

Preparation or mixture (INFERRED, derived from record counts)
Basis: PubChem returned no compound record for this name, so the subject is a preparation, protein or mixture rather than a defined small molecule; identity fields are unsourced.
This label counts record types. It is not an assessment of clinical efficacy, of safety, of study quality or of consensus, and it does not rank one compound above another.

What the corpus does not carry for this compound

• Identity fields with no source retrieved: cas, pubchem_cid, uniprot_id, molecular_formula, molecular_weight, sequence.
• Reported half-life: no source retrieved, so the value reads Unknown.
• Amounts reported in the cited literature: no row recorded.
• Adverse effects reported in the cited literature: no row recorded.
• Long-form mechanism: not written, because no source was read in full.
• Records the query returned that this corpus does not carry: 182.

An absent row records the absence of a retrieved report, never the absence of the thing itself.

Application register

A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.^[1]

Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.

The records

Where this page sits

Receptor targets

• GIP receptor: every compound in scope acting at it
• GLP-1 receptor: every compound in scope acting at it
• Glucagon receptor: every compound in scope acting at it

Curated pairs

• Retatrutide and Tirzepatide, side by side

All compounds in scope: the trial index. Coverage by endpoint: the endpoint index.

Review status

Review tier

High impact

State

Pending qualified review

Compiled by

automated pipeline

Qualified clinical review

None on record

Why this tier was assigned

• 3 indexed record(s) are interventional human trials
• the class covers weight-management and metabolic prescribing, the highest-risk consumer subject in this corpus

Checks the pipeline performed

• every cited source id resolves to a sources[] row on the entity
• every identifier is a well-formed PMID or DOI
• study model derived only from assigned MeSH headings and publication types
• banned-phrase lint over rendered HTML including title, meta, alt and JSON-LD
• unknown values render as the literal word Unknown

Checks the pipeline did not perform

• no full text was read
• no clinical appraisal of any study
• no assessment of whether the indexed set is representative of the literature

A high_impact profile with qualified_review null must not be published as indexable. Compilation and linting are not clinical validation.

Sources

1. Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:retatrutide
2. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med (2023). pmid:37366315
3. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet (2023). pmid:37385280
4. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med (2024). pmid:38858523
5. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. Lancet Diabetes Endocrinol (2025). pmid:40609566
6. A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity. Eur J Clin Pharmacol (2024). pmid:38367045